WallStreetZenWallStreetZen

NASDAQ: CTNM
Contineum Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CTNM

Based on 4 analysts offering 12 month price targets for Contineum Therapeutics Inc

Min Forecast
$16.00+27.39%
Avg Forecast
$20.50+63.22%
Max Forecast
$24.00+91.08%

Should I buy or sell CTNM stock?

Based on 4 analysts offering ratings for Contineum Therapeutics Inc.

Buy
Strong Buy
1 analysts 25%
Buy
2 analysts 50%
Hold
1 analysts 25%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CTNM's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates CTNM as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their CTNM stock forecasts and price targets.

CTNM stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-09-15
lockedlocked$00.00+00.00%2026-09-15
lockedlocked$00.00+00.00%2026-07-31
lockedlocked$00.00+00.00%2026-05-14

1 of 1

Forecast return on equity

Is CTNM forecast to generate an efficient return?

Company
-32.12%
Industry
22.19%
Market
168.26%
CTNM's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CTNM forecast to generate an efficient return on assets?

Company
-30.75%
Industry
23.8%
CTNM is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CTNM earnings per share forecast

What is CTNM's earnings per share in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
-$1.75
Avg 2 year Forecast
-$1.98
Avg 3 year Forecast
-$1.90

CTNM revenue forecast

What is CTNM's revenue in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$7.0M
Avg 2 year Forecast
$2.2M
Avg 3 year Forecast
$2.6M

CTNM vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CTNM$12.56$20.50+63.22%Buy
ENTX$2.75$9.67+252.17%Strong Buy
OVID$2.40$7.00+191.67%Buy
ASMB$23.67$47.50+100.68%Strong Buy
TECX$23.67$83.00+250.65%Strong Buy
View Top Biotech Stocks

Contineum Therapeutics Stock Forecast FAQ

Is Contineum Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: CTNM) stock is to Buy CTNM stock.

Out of 4 analysts, 1 (25%) are recommending CTNM as a Strong Buy, 2 (50%) are recommending CTNM as a Buy, 1 (25%) are recommending CTNM as a Hold, 0 (0%) are recommending CTNM as a Sell, and 0 (0%) are recommending CTNM as a Strong Sell.

If you're new to stock investing, here's how to buy Contineum Therapeutics stock.

What is CTNM's earnings growth forecast for 2026-2028?

(NASDAQ: CTNM) Contineum Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.78%.

Contineum Therapeutics's earnings in 2026 is -$57,558,000.On average, 9 Wall Street analysts forecast CTNM's earnings for 2026 to be -$65,727,880, with the lowest CTNM earnings forecast at -$68,207,112, and the highest CTNM earnings forecast at -$60,043,327. On average, 9 Wall Street analysts forecast CTNM's earnings for 2027 to be -$74,388,264, with the lowest CTNM earnings forecast at -$94,015,209, and the highest CTNM earnings forecast at -$56,488,130.

In 2028, CTNM is forecast to generate -$71,438,768 in earnings, with the lowest earnings forecast at -$84,798,032 and the highest earnings forecast at -$52,142,889.

What is CTNM's revenue growth forecast for 2026-2028?

(NASDAQ: CTNM) Contineum Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.84%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.9%.

Contineum Therapeutics's revenue in 2026 is $0.On average, 8 Wall Street analysts forecast CTNM's revenue for 2026 to be $264,137,968, with the lowest CTNM revenue forecast at $0, and the highest CTNM revenue forecast at $1,185,065,658. On average, 7 Wall Street analysts forecast CTNM's revenue for 2027 to be $84,421,820, with the lowest CTNM revenue forecast at $0, and the highest CTNM revenue forecast at $434,524,075.

In 2028, CTNM is forecast to generate $98,830,714 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $406,872,543.

What is CTNM's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: CTNM) forecast ROA is -30.75%, which is lower than the forecast US Biotechnology industry average of 23.8%.

What is CTNM's Price Target?

According to 4 Wall Street analysts that have issued a 1 year CTNM price target, the average CTNM price target is $20.50, with the highest CTNM stock price forecast at $24.00 and the lowest CTNM stock price forecast at $16.00.

On average, Wall Street analysts predict that Contineum Therapeutics's share price could reach $20.50 by Sep 15, 2027. The average Contineum Therapeutics stock price prediction forecasts a potential upside of 63.22% from the current CTNM share price of $12.56.

What is CTNM's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: CTNM) Contineum Therapeutics's current Earnings Per Share (EPS) is -$1.73. On average, analysts forecast that CTNM's EPS will be -$1.75 for 2026, with the lowest EPS forecast at -$1.81, and the highest EPS forecast at -$1.60. On average, analysts forecast that CTNM's EPS will be -$1.98 for 2027, with the lowest EPS forecast at -$2.50, and the highest EPS forecast at -$1.50. In 2028, CTNM's EPS is forecast to hit -$1.90 (min: -$2.25, max: -$1.39).

What is CTNM's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: CTNM) forecast ROE is -32.12%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.